This Plain Language Summary of Publication article (PLSP) from Future Oncology describes the first study evaluating subcutaneous (under-the-skin) administration of isatuximab for multiple myeloma patients. While isatuximab is already approved in various countries as an intravenous treatment for this blood cancer, the subcutaneous method using a new on-body delivery system (OBDS) could reduce treatment time and decrease nursing requirements.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma’ and was published in Haematologica.

Visit Ferrata-Storti Foundation using the link to read the original article.